CN115161264A - 一种体外培养老龄成纤维细胞的培养体系及培养方法和应用 - Google Patents
一种体外培养老龄成纤维细胞的培养体系及培养方法和应用 Download PDFInfo
- Publication number
- CN115161264A CN115161264A CN202211092124.8A CN202211092124A CN115161264A CN 115161264 A CN115161264 A CN 115161264A CN 202211092124 A CN202211092124 A CN 202211092124A CN 115161264 A CN115161264 A CN 115161264A
- Authority
- CN
- China
- Prior art keywords
- culture
- fibroblasts
- culturing
- vitro
- aged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 94
- 238000000338 in vitro Methods 0.000 title claims abstract description 29
- 238000012136 culture method Methods 0.000 title claims abstract description 17
- 238000012258 culturing Methods 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 238000007877 drug screening Methods 0.000 claims abstract description 8
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 238000011084 recovery Methods 0.000 claims abstract description 4
- -1 p-toluenesulfonyl Chemical group 0.000 claims description 86
- 210000004027 cell Anatomy 0.000 claims description 59
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 108010010803 Gelatin Proteins 0.000 claims description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- 239000008188 pellet Substances 0.000 claims description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 10
- 239000013049 sediment Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 9
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 9
- 239000004473 Threonine Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 9
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 9
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 9
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 9
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 9
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 9
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 9
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 9
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 9
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000012588 trypsin Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 5
- 229960002079 calcium pantothenate Drugs 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- 229960005337 lysine hydrochloride Drugs 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 2
- ASVYXWZOBCRSFB-UHFFFAOYSA-N C(C)S(=O)(O)=S.OCCN1CCNCC1 Chemical compound C(C)S(=O)(O)=S.OCCN1CCNCC1 ASVYXWZOBCRSFB-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 229930003471 Vitamin B2 Natural products 0.000 claims 1
- 239000011716 vitamin B2 Substances 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 15
- 230000006907 apoptotic process Effects 0.000 abstract description 9
- 230000007774 longterm Effects 0.000 abstract description 9
- 206010052428 Wound Diseases 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 238000012423 maintenance Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000010276 construction Methods 0.000 abstract description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 9
- 229960004295 valine Drugs 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- 229960001153 serine Drugs 0.000 description 8
- 229960002898 threonine Drugs 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229960005190 phenylalanine Drugs 0.000 description 7
- 229960003136 leucine Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 235000019743 Choline chloride Nutrition 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 4
- 229930182844 L-isoleucine Natural products 0.000 description 4
- 239000004395 L-leucine Substances 0.000 description 4
- 235000019454 L-leucine Nutrition 0.000 description 4
- 229930195722 L-methionine Natural products 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- HHGZUQPEIHGQST-UHFFFAOYSA-N [2-[(2-azaniumyl-2-carboxyethyl)disulfanyl]-1-carboxyethyl]azanium;dichloride Chemical compound Cl.Cl.OC(=O)C(N)CSSCC(N)C(O)=O HHGZUQPEIHGQST-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 4
- 229960003178 choline chloride Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012418 validation experiment Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ACLYHRKZVACTBD-JZGIKJSDSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;dihydrate Chemical compound O.O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ACLYHRKZVACTBD-JZGIKJSDSA-N 0.000 description 1
- GBKVTQSWZCBVSL-FHAQVOQBSA-N (2s,3s)-2-amino-3-methylpentanoic acid;hydrochloride Chemical compound Cl.CC[C@H](C)[C@H](N)C(O)=O GBKVTQSWZCBVSL-FHAQVOQBSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- WFTCFVUQORELJZ-USHJOAKVSA-L disodium;(2s)-2-amino-3-(4-oxidophenyl)propanoate;dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)[C@@H](N)CC1=CC=C([O-])C=C1 WFTCFVUQORELJZ-USHJOAKVSA-L 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
本发明公开了一种体外培养老龄成纤维细胞的培养体系及培养方法和应用,属于生物与新医药技术领域,具体来说,涉及一种体外培养老龄成纤维细胞的培养体系、采用培养体系进行体外培养老龄成纤维细胞的培养方法,基于体外培养老龄成纤维细胞的培养体系和培养方法的应用。本发明通过培养体系各组分间的协同作用,优化后的培养方法,能够实现在体外长期并稳定的维持老龄成纤维细胞增殖,抑制老龄成纤维细胞的凋亡,显著提高老龄成纤维细胞的增殖速度,实现长期稳定培养,培养出的老龄成纤维细胞能在构建药物筛选平台,在延缓衰老药物中的应用和在制备促进伤口恢复药物中具有良好的应用。
Description
技术领域
本发明涉及生物与新医药技术领域,具体涉及一种体外培养老龄成纤维细胞的培养体系及培养方法和应用。
背景技术
成纤维细胞的状态可以间接的反应个体相应年龄的身体状态,包括代谢能力和细胞增殖能力。处于衰老时期的成纤维细胞增殖能力弱,因此对于衰老的成纤维细胞的长期稳定培养比较困难,细胞资源使用次数有限,这一现象限制了对老龄人群在再生医学方面的研究。由于老龄成纤维细胞的培养有较大的技术难度,而现有技术中关于老龄成纤维细胞的培养尚未见报道。
发明内容
为了解决上述技术问题,本发明提供了一种体外培养老龄成纤维细胞的培养体系及培养方法和应用,解决了现有技术中处于衰老时期的成纤维细胞增殖能力弱及长期稳定培养困难的技术问题。
为了实现上述目的,本发明采用如下技术方案:
第一方面,本发明提供一种体外培养老龄成纤维细胞的培养体系,由如下组分构成:
Glycine(甘氨酸,0.1-1mM),Choline chloride(胆碱,0.01-0.1mM),D-Calciumpantothenate(泛酸钙,0.001-0.01mM),Folic Acid(叶酸,0.001-0.01mM),Niacinamide(烟酰胺,0.01-0.1mM),Pyridoxine hydrochloride(盐酸吡哆醇,0.01-0.1mM),Riboflavin(维生素B2,0.001-0.01mM),Thiamine hydrochloride(盐酸硫胺素,0.01-0.1mM),i-Inositol(肌醇,0.01-0.1mM),L-Arginine hydrochloride(对甲苯磺酰,0.1-1mM),L-Cystine 2HCl(l -胱氨酸二盐酸,0.1-1mM),L-Glutamine(谷氨酰胺,1-10mM),L-Histidine hydrochloride-H2O(组氨酸盐酸盐,0.1-1mM),L-Isoleucine(异亮氨酸,0.01-10mM),L-Leucine(亮氨酸,0.01-10mM),L-Lysine hydrochloride(盐酸赖氨酸,0.01-10mM),L-Methionine(甲硫氨酸,0.01-10mM),L-Phenylalanine(苯丙胺酸,0.01-10mM),L-Serine(丝氨酸,0.01-10mM),L-Threonine(苏氨酸,0.01-10mM),L-Tryptophan(左旋色氨酸,0.01-10mM),L-Tyrosine disodium salt dihydrate(络氨酸二钠盐二水化合物,0.01-10mM),L-Valine(缬氨酸,0.01-10mM),Calcium Chloride(乳化剂,1-10mM),FerricNitrat(硝酸铁,0.0001-0.001mM),Magnesium Sulfate(硫酸镁,0.1-1mM),PotassiumChloride(氯化钾,1-10mM),Sodium Bicarbonate(碳酸氢钠,10-100mM),Sodium Chloride(氯化钠,10-100mM),Sodium Phosphate monobasic(磷酸二氢钠,0.1-1mM),D-Glucose(葡萄糖,1-100mM),HEPES(羟乙基哌嗪乙硫磺酸,10-100mM),Glutathione(谷胱甘肽,0.01-1mM),FBS(胎牛血清,5-20%)。
由于细胞生长是受细胞内非常复杂的网络调控,不同的氨基酸或化合物对细胞信号通路具有不同的影响,通过大量的试验验证,本申请的培养体系,能够改变老龄成纤维细胞转录组水平和氧化磷酸化水平的变化;且培养体系中,每一个成分的添加都会对细胞产生很大影响。本申请在做前期研究中发现,类似DMEM-F12培养基的成份或其它培养条件,并不能维持成纤维细胞生长,不能养活老龄成纤维细胞。
本发明专利的培养体系由无菌蒸溜水与15种氨基酸,8种维生素,7中无机盐和血清等组分组成,通过各组分间的协同作用,能够实现在体外抑制老龄/高代次的成纤维细胞的凋亡,提高老龄成纤维细胞的增殖速度,实现长期稳定培养。培养体系的配置:例如,取1L无菌蒸溜水,加入对应浓度或质量百分数的组分进行混匀即可,培养体系根据用量进行配制。
第二方面,本发明提供采用第一方面的体外培养老龄成纤维细胞的培养体系进行体外老龄成纤维细胞的培养方法,包括如下步骤:
(1)用明胶包被多个培养皿并在培养箱中放置0.5h-96h,待包被完成后,将每个培养皿内的明胶吸出,获得多个包被后的培养皿A;
(2)将老龄成纤维细胞用胰蛋白酶消化,待老龄成纤维细胞逐渐消化为单个老龄成纤维细胞后获得细胞液;将所述细胞液转入离心管中进行离心分离,待离心分离完毕,弃上清液,获得细胞沉淀;
(3)将步骤(2)中的细胞沉淀用所述培养体系重悬,重悬结束后接种于步骤(1)中所述的一个培养皿A中,置于培养箱中培养;经培养3-4天后即可增殖出大量的老龄成纤维细胞。
本申请正是优化了整个培养体系及培养方法,通过培养体系各组分间的作用,及优化后的培养方法,能够实现在体外长期并稳定的维持老龄成纤维细胞增殖,抑制老龄成纤维细胞的凋亡,显著提高老龄成纤维细胞的增殖速度,实现长期稳定培养。
通过若干次设置不同培养条件及优化培养成份,从整体上考量培养体系的效果,筛选出能促进老龄成纤维细胞增殖,抑制其凋亡的一套培养体系及培养方法。本发明中的培养体系,使老龄成纤维细胞可以存活并大量增殖,如更改或替换培养体系中的组分或含量,则会使老龄成纤维细胞不能存活,更不可能增殖。本发明中的培养体系还可对人、猴、鼠、牛、猪等物种的老龄成纤维细胞进行培养应用。
优选地,步骤(1)中所述明胶的质量百分比为0.01-5%。
优选地,步骤(2)中所述离心分离的转速为400-3000 rpm,离心分离时间为2-10min。
优选地,步骤(1)和步骤(3)中所述培养箱中的温度均为37℃。
第三方面,使用第一方面所述的体外培养老龄成纤维细胞的培养体系或根据第二方面所述的体外培养老龄成纤维细胞的培养方法,在如下(a1)、(a2)至少一种中的应用:
(a1)构建药物筛选平台,在延缓衰老药物中的应用;
(a2)在制备促进伤口恢复药物中的应用。
综上所述,相比于现有技术,本发明的优点在于:
1、本发明提供的老龄成纤维细胞的培养体系及培养方法,通过培养体系各组分间的协同作用,优化后的培养方法,能够实现在体外长期并稳定的维持老龄成纤维细胞增殖,抑制老龄成纤维细胞的凋亡,显著提高老龄成纤维细胞的增殖速度,实现长期稳定培养。
2、本发明通过体外培养老龄成纤维细胞,不仅有助于对皮肤抗衰的探索,还有助于针对老龄细胞体外进行药物筛选,减少研发成本;本发明还能在制备促进伤口恢复药物中进行应用。
附图说明
图1是本发明的成纤维细胞培养的明场图;
图2是本发明成纤维细胞的数量图;
图3是本发明的成纤维细胞培养的细胞凋亡检测图;
图4是本发明的运用于药物筛选的实例;
图5是本发明促进伤口恢复实例。
具体实施方式
下面对本发明作进一步说明。
实施例1
本实施例提供的体外培养老龄成纤维细胞的方法,具体步骤为:
(1)提前0.5h用5%的明胶对后续实验将要用到的多个培养皿进行包被(用移液枪将明胶液体吸入培养皿中),液体应覆盖皿底,并放入37℃培养箱,待包被完成后,将每个培养皿内的明胶吸出,获得多个包被后的培养皿。
(2)配制老龄成纤维细胞培养体系:在1L无菌蒸溜水中加入以下组分,
Glycine(甘氨酸,0.1mM),Choline chloride(胆碱,0.01mM),D-Calciumpantothenate(泛酸钙,0.001mM),Folic Acid(叶酸,0.001mM),Niacinamide(烟酰胺,0.01mM),Pyridoxine hydrochloride(盐酸吡哆醇,0.01mM),Riboflavin(维生素B2,0.001mM),Thiamine hydrochloride(盐酸硫胺素,0.01mM),I-inositol(肌醇,0.01mM),L-Arginine hydrochloride(对甲苯磺酰,0.1mM),L-Cystine 2HCl(l -胱氨酸二盐酸,0.1mM),L-Glutamine(谷氨酰胺,1mM),L-Histidine hydrochloride-H2O(组氨酸盐酸盐,0.1mM),L-Isoleucine(异亮氨酸,0.01mM),L-Leucine(亮氨酸,0.01mM),L-Lysinehydrochloride(盐酸赖氨酸,0.01mM),L-Methionine(甲硫氨酸,0.01mM),L-Phenylalanine(苯丙胺酸,0.01mM),L-Serine(丝氨酸,0.01mM),L-Threonine(苏氨酸,0.01mM),L-Tryptophan(左旋色氨酸,0.01mM),L-Tyrosine disodium salt dihydrate(络氨酸二钠盐二水化合物,0.01mM),L-Valine(缬氨酸,0.01mM),Calcium Chloride(乳化剂,1mM),Ferric Nitrat(硝酸铁,0.0001mM),Magnesium Sulfate(硫酸镁,0.1mM),PotassiumChloride(氯化钾,1mM),Sodium Bicarbonate(碳酸氢钠,10mM),Sodium Chloride(氯化钠,10mM),Sodium Phosphate monobasic(磷酸二氢钠,0.1mM),D-Glucose(葡萄糖,1mM),HEPES(羟乙基哌嗪乙硫磺酸,10mM),Glutathione(谷胱甘肽,0.01mM),FBS(胎牛血清,20%)。
(3)将老龄成纤维细胞用胰蛋白酶消化,待细胞逐渐消化为单个老龄成纤维细胞后,获得细胞液;将细胞液转入离心管中在3000 rpm下离心分离2min,待离心分离完毕,弃上清液,获得细胞沉淀。
胰蛋白酶消化的步骤为:弃原培养皿中的培养液,PBS洗涤一次后弃掉PBS,将胰蛋白酶消化液用移液枪转移至培养皿中,放入37˚培养箱中。
(4)将细胞沉淀用步骤(2)的培养体系重悬,重悬结束后接种于步骤(1)中的一个包被后的培养皿中,置于37℃培养箱中培养;经培养3天后即可增殖出大量的老龄成纤维细胞。
重悬步骤为:用移液枪将培养液吸出,随后缓和的将移液枪中的液体打入沉淀中,利用移液枪将液体与沉淀反复混合。
实施例2
本实施例提供的体外培养老龄成纤维细胞的方法,具体步骤为:
(1)提前96h用0.01%的明胶对后续实验将要用到的多个培养皿进行包被,液体应覆盖皿底,并放入37℃培养箱,待包被完成后,将每个培养皿内的明胶吸出,获得多个包被后的培养皿。
(2)配制老龄成纤维细胞培养体系:在1L无菌蒸溜水中加入以下组分,
Glycine(甘氨酸,1mM),Choline chloride(胆碱,0.1mM),D-Calciumpantothenate(泛酸钙,0.01mM),Folic Acid(叶酸,0.01mM),Niacinamide(烟酰胺,0.1mM),Pyridoxine hydrochloride(盐酸吡哆醇, 0.1mM),Riboflavin(维生素B2,0.01mM),Thiamine hydrochloride(盐酸硫胺素,0.1mM),i-Inositol(肌醇,0.1mM),L-Arginine hydrochloride(对甲苯磺酰,1mM),L-Cystine 2HCl(l -胱氨酸二盐酸,1mM),L-Glutamine(谷氨酰胺,10mM),L-Histidine hydrochloride-H2O(组氨酸盐酸盐,1mM),L-Isoleucine(异亮氨酸,10mM),L-Leucine(亮氨酸,10mM),L-Lysine hydrochloride(盐酸赖氨酸,10mM),L-Methionine(甲硫氨酸,10mM),L-Phenylalanine(苯丙胺酸,10mM),L-Serine(丝氨酸,10mM),L-Threonine(苏氨酸,10mM),L-Tryptophan(左旋色氨酸,10mM),L-Tyrosine disodium salt dihydrate(络氨酸二钠盐二水化合物,10mM),L-Valine(缬氨酸,10mM),Calcium Chloride(乳化剂,10mM),Ferric Nitrat(硝酸铁,0.001mM),Magnesium Sulfate(硫酸镁,1mM),Potassium Chloride(氯化钾,10mM),SodiumBicarbonate(碳酸氢钠,100mM),Sodium Chloride(氯化钠,100mM),Sodium Phosphatemonobasic(磷酸二氢钠,1mM),D-Glucose(葡萄糖,100mM),HEPES(羟乙基哌嗪乙硫磺酸,100mM),Glutathione(谷胱甘肽,1mM),FBS(胎牛血清,5%)
(3)将老龄成纤维细胞用胰蛋白酶消化,待细胞逐渐消化为单个老龄成纤维细胞后,获得细胞液;将细胞液转入离心管中于400rpm进行离心分离10min,待离心完毕,弃上清液,获得细胞沉淀。
(4)将细胞沉淀用步骤(2)的培养体系重悬,重悬结束后接种于步骤(1)中的一个包被后的培养皿中,置于37℃培养箱中培养;经培养4天后即可增殖出大量的老龄成纤维细胞。
实施例3
本实施例提供的体外培养老龄成纤维细胞的方法,如图1所示,具体步骤为:
(1)提前96h用0.01%的明胶对后续实验将要用到的多个培养皿进行包被,液体应覆盖皿底,并放入37℃培养箱,待包被完成后,将每个培养皿内的明胶吸出,获得多个包被后的培养皿;
(2)配制老龄成纤维细胞培养体系:在1L无菌蒸溜水中加入以下组分,
Glycine(甘氨酸,0.5mM),Choline chloride(胆碱,0.05mM),D-Calciumpantothenate(泛酸钙,0.005mM),Folic Acid(叶酸,0.005mM),Niacinamide(烟酰胺,0.05mM),Pyridoxine hydrochloride(盐酸吡哆醇, 0.05mM),Riboflavin(维生素B2,0.005mM),Thiamine hydrochloride(盐酸硫胺素,0.05mM),i-Inositol(肌醇,0.05mM),L-Arginine hydrochloride(对甲苯磺酰,0. 5mM),L-Cystine 2HCl(l -胱氨酸二盐酸,0.5mM),L-Glutamine(谷氨酰胺,5mM),L-Histidine hydrochloride-H2O(组氨酸盐酸盐,0.5mM),L-Isoleucine(异亮氨酸,5mM),L-Leucine(亮氨酸,5mM),L-Lysinehydrochloride(盐酸赖氨酸,5mM),L-Methionine(甲硫氨酸,5mM),L-Phenylalanine(苯丙胺酸,5mM),L-Serine(丝氨酸,5mM),L-Threonine(苏氨酸,5mM),L-Tryptophan(左旋色氨酸,5mM),L-Tyrosine disodium salt dihydrate(络氨酸二钠盐二水化合物,5mM),L-Valine(缬氨酸,5mM),Calcium Chloride(乳化剂,5mM),Ferric Nitrat(硝酸铁,0.0005mM),Magnesium Sulfate(硫酸镁,0.5mM),Potassium Chloride(氯化钾,5mM),Sodium Bicarbonate(碳酸氢钠,50mM),Sodium Chloride(氯化钠,50mM),SodiumPhosphate monobasic(磷酸二氢钠,0.5mM),D-Glucose(葡萄糖,50mM),HEPES(羟乙基哌嗪乙硫磺酸,50mM),Glutathione(谷胱甘肽,0.05mM),FBS(胎牛血清,12%)
(3)将老龄成纤维细胞用胰蛋白酶消化,待细胞逐渐消化为单个老龄成纤维细胞后,获得细胞液;将细胞液转入离心管中于2000rpm进行离心分离5min,待离心完毕,弃上清液,获得细胞沉淀。
(4)将细胞沉淀用步骤(2)中的培养体系重悬,重悬后转移至步骤(1)的一个包被后的培养皿中,将培养皿放入37℃培养箱中培养,培养3后即可增殖出大量的老龄成纤维细胞。
对比例1
本对比例提供改良前老龄成纤维细胞的培养体系及培养方法。
改良前老龄成纤维细胞的培养体系:商业化Dulbecco 改良 Eagle 培养基(DMEM,90%),FBS(胎牛血清,10%)
培养方法为:
(1)将老龄成纤维细胞用胰蛋白酶消化,待细胞逐渐消化为单个老龄成纤维细胞后,获得细胞液;将细胞液转入离心管中在3000 rpm下离心分离2min,待离心分离完毕,弃上清液,获得细胞沉淀。
(2)将细胞沉淀用改良前的培养体系重悬,重悬结束后接种于培养皿中,置于37℃培养箱中培养。培养3天后即可增殖出老龄成纤维细胞。
实施例4 实施例3的验证实验
将实施例3中增殖出的老龄成纤维细胞与对比例1中增殖出的老龄成纤维细胞进行对比验证。
4.1增殖能力验证实验:
将实施例3中增殖出的大量老龄成纤维细胞的培养皿与对比例1中培养出的老龄成纤维细胞培养皿用显微镜记录实验现象。如图1所示,可以发现单位面积改良前与改良后的培养体系对细胞形态和增殖能力影响较大,改良后的培养体系能显著提高老龄成纤维细胞的增殖能力。
将培养皿中的细胞消化后计数,实验结果如图2所示。由图2可看出,在起始细胞数量相同的情况下,改良后培养体系的培养皿中的成纤维细胞形态和增殖能力有较大改善。
4.2细胞凋亡验证实验:
将实施例3中增殖出的老龄成纤维细胞与对比例1中培养出的老龄成纤维细胞进行SA-β-gal染色,用于验证细胞凋亡。
SA-β-gal染色染色步骤(以6孔板贴壁细胞为例):
a. 对于6孔板中培养的细胞,吸除细胞培养液,用PBS或HBSS洗涤1次,加入1毫升β-半乳糖苷酶染色固定液,室温固定15分钟。对于其它类型的培养板,固定液及后续溶液的用量参照此比例进行操作。
b. 吸除细胞固定液,用PBS或HBSS洗涤细胞3次,每次3分钟。
c. 吸除PBS或HBSS,每孔加入1毫升染色工作液。
d. 37℃孵育过夜,可以用parafilm或保鲜膜封住6孔板防止蒸发。注意:37℃孵育不能在二氧化碳培养箱中进行。
e. 普通光学显微镜下观察。如不能及时观察计数,可以去除染色工作液,加入2毫升PBS,4℃可以保存数天;或者加上封片液封片后,4℃可以保存较长时间。
实验结果如图3所示,由图3的染色结果中看出,改良后的着色细胞数量更少(着色细胞代表凋亡的细胞),本发明的培养体系能够抑制细胞凋亡。
实施例5构建药物筛选平台、在延缓衰老药物中的应用实例
改良后的培养体系能够维持老龄成纤维细胞的增殖,因此对生长在改良后体系中的老龄成纤维进行药物筛选,可以用于延缓衰老药物的开发。
具体筛选过程为:
a. 提前将需要筛选的化合物或蛋白溶入本发明的老龄成纤维细胞培养体系中;
b. 提前一天按照相同细胞数目接种于培养皿的细胞,弃上清,PBS洗涤一次后加入a中准备的含筛选化合物的培养液;
c. 培养在37˚,5% CO2的培养环境中,固定时间每天对细胞进行计数,最终评估化合物或药物对细胞的影响。
由图4可看出,基于本体系的生长环境下,可同时对不同药物进行筛选。
实施例6促进伤口恢复应用实例
将实施例3中增殖出的老龄成纤维细胞涂抹于动物伤口,同时设对照组,对照组的动物伤口不进行任何处理。伤口愈合情况如图5所示,由图5可看出,用本体系增殖出的老龄成纤维细胞处理伤口,伤口愈合时间显著缩短。老龄成纤维细胞可有助于伤口愈合。
在本说明书的描述中,参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (6)
1.一种体外培养老龄成纤维细胞的培养体系,其特征在于,由如下组分构成:0.1-1mM甘氨酸、0.01-0.1mM胆碱、0.001-0.01mM泛酸钙、0.001-0.01mM叶酸、0.01-0.1mM烟酰胺、0.01-0.1mM盐酸吡哆醇、0.001-0.01mM维生素B2、0.01-0.1mM盐酸硫胺素、0.01-0.1mM肌醇、0.1-1mM对甲苯磺酰、0.1-1mMl -胱氨酸二盐酸、1-10mM谷氨酰胺、0.1-1mM组氨酸盐酸盐、0.01-10mM异亮氨酸、0.01-10mM亮氨酸、0.01-10mM盐酸赖氨酸、0.01-10mM甲硫氨酸、0.01-10mM苯丙胺酸、0.01-10mM丝氨酸、0.01-10mM苏氨酸、0.01-10mM左旋色氨酸、0.01-10mM络氨酸二钠盐二水化合物、0.01-10mM缬氨酸、1-10mM乳化剂、0.0001-0.001mM硝酸铁、0.1-1mM硫酸镁、1-10mM氯化钾、10-100mM碳酸氢钠、10-100mM氯化钠、0.1-1mM磷酸二氢钠、1-100mM葡萄糖、10-100mM羟乙基哌嗪乙硫磺酸、0.01-1mM谷胱甘肽、5-20%血清。
2.根据权利要求1所述的一种体外培养老龄成纤维细胞的培养体系进行体外培养老龄成纤维细胞的培养方法,其特征在于,包括如下步骤:
(1)用明胶包被多个培养皿并在培养箱中放置0.5h-96h,待包被完成后,将每个培养皿内的明胶吸出,获得多个包被后的培养皿A;
(2)将老龄成纤维细胞用胰蛋白酶消化,待老龄成纤维细胞逐渐消化为单个老龄成纤维细胞后,获得细胞液;将所述细胞液转入离心管中进行离心分离,待离心分离完毕,弃上清液,获得细胞沉淀;
(3)将步骤(2)中的细胞沉淀用所述培养体系重悬,重悬结束后接种于步骤(1)中所述的一个培养皿A中,置于培养箱中培养;经培养3-4天后即可增殖出大量的老龄成纤维细胞。
3.根据权利要求2所述的体外培养老龄成纤维细胞的培养方法,其特征在于,步骤(1)中所述明胶的质量百分比为0.01-5%。
4.根据权利要求2所述的体外培养老龄成纤维细胞的培养方法,其特征在于,步骤(2)中所述离心分离的转速为400-3000 rpm,离心分离时间为2-10min。
5.根据权利要求2所述的体外培养老龄成纤维细胞的培养方法,其特征在于,步骤(1)和步骤(3)中所述培养箱中的温度均为37℃。
6.根据权利要求1所述的体外培养老龄成纤维细胞的培养体系或根据权利要求2-5任一项所述的体外培养老龄成纤维细胞的培养方法,在如下(a1)、(a2)至少一种中的应用:
(a1)构建药物筛选平台,在延缓衰老药物中的应用;
(a2)在制备促进伤口恢复药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211092124.8A CN115161264A (zh) | 2022-09-08 | 2022-09-08 | 一种体外培养老龄成纤维细胞的培养体系及培养方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211092124.8A CN115161264A (zh) | 2022-09-08 | 2022-09-08 | 一种体外培养老龄成纤维细胞的培养体系及培养方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115161264A true CN115161264A (zh) | 2022-10-11 |
Family
ID=83480425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211092124.8A Pending CN115161264A (zh) | 2022-09-08 | 2022-09-08 | 一种体外培养老龄成纤维细胞的培养体系及培养方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115161264A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001114636A (ja) * | 1999-10-14 | 2001-04-24 | Noevir Co Ltd | ヒアルロン酸産生及びカタラーゼ産生促進剤、線維芽細胞賦活剤、並びに皮膚外用剤 |
US20070160586A1 (en) * | 2005-06-15 | 2007-07-12 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
CN106434550A (zh) * | 2016-04-28 | 2017-02-22 | 王晓冰 | 一种改良的PPCs细胞培养方法 |
CN107217027A (zh) * | 2017-06-30 | 2017-09-29 | 太仓东浔生物科技有限公司 | 一种高营养细胞扩大培养的方法 |
CN109112101A (zh) * | 2017-06-26 | 2019-01-01 | 拜西欧斯(北京)生物技术有限公司 | 一种成纤维细胞培养基及其应用 |
CN111849879A (zh) * | 2020-08-07 | 2020-10-30 | 张娇 | 一种细胞培养基及细胞培养方法 |
CN113403262A (zh) * | 2021-06-23 | 2021-09-17 | 昆明理工大学 | 一种对食蟹猴干细胞的无饲养层培养方法 |
CN114891730A (zh) * | 2022-04-29 | 2022-08-12 | 诺赛联合(北京)生物医学科技有限公司 | 一种用于扩增成纤维细胞的培养基及其制备方法 |
-
2022
- 2022-09-08 CN CN202211092124.8A patent/CN115161264A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001114636A (ja) * | 1999-10-14 | 2001-04-24 | Noevir Co Ltd | ヒアルロン酸産生及びカタラーゼ産生促進剤、線維芽細胞賦活剤、並びに皮膚外用剤 |
US20070160586A1 (en) * | 2005-06-15 | 2007-07-12 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
CN106434550A (zh) * | 2016-04-28 | 2017-02-22 | 王晓冰 | 一种改良的PPCs细胞培养方法 |
CN109112101A (zh) * | 2017-06-26 | 2019-01-01 | 拜西欧斯(北京)生物技术有限公司 | 一种成纤维细胞培养基及其应用 |
CN107217027A (zh) * | 2017-06-30 | 2017-09-29 | 太仓东浔生物科技有限公司 | 一种高营养细胞扩大培养的方法 |
CN111849879A (zh) * | 2020-08-07 | 2020-10-30 | 张娇 | 一种细胞培养基及细胞培养方法 |
CN113403262A (zh) * | 2021-06-23 | 2021-09-17 | 昆明理工大学 | 一种对食蟹猴干细胞的无饲养层培养方法 |
CN114891730A (zh) * | 2022-04-29 | 2022-08-12 | 诺赛联合(北京)生物医学科技有限公司 | 一种用于扩增成纤维细胞的培养基及其制备方法 |
Non-Patent Citations (3)
Title |
---|
JUNG JY等: "Human dermal stem/progenitor cell-derived conditioned medium improves senescent human dermal fibro blasts", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
喻陆等: "松花粉对衰老成纤维细胞线粒体DNA缺失突变的影响", 《中国老年学杂志》 * |
沈彬等: "纯钛表面不同处理方法对成纤维细胞生长影响的研究", 《安徽医科大学学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Culture conditions and types of growth media for mammalian cells | |
CN105229145B (zh) | 片状细胞培养物的制造方法 | |
JP5436905B2 (ja) | シート状細胞培養物の製造方法 | |
US20160230143A1 (en) | Chemically defined culture medium for stem cell maintenance and differentiation | |
Takahashi et al. | Harvest of quality-controlled bovine myogenic cells and biomimetic bovine muscle tissue engineering for sustainable meat production | |
CN102653728A (zh) | 一种用生物反应器和微载体逐级放大培养动物细胞的方法 | |
Öhman et al. | Glutamine is not an essential amino acid for Sf-9 insect cells | |
CN102191215A (zh) | 一种人源性无血清培养基及其制备方法 | |
JP2024054301A (ja) | シート状細胞培養物の製造方法 | |
CN114606200A (zh) | Sp2/0细胞培养基及生产重组犬细小病毒单克隆抗体的方法 | |
CN115161264A (zh) | 一种体外培养老龄成纤维细胞的培养体系及培养方法和应用 | |
WO2016187451A1 (en) | Multi-pathway induction of stem cell differentiation with rna | |
KR20190010490A (ko) | 관류식 바이오 리엑터를 사용한 세포밖 소포체 분비량 향상 방법 및 이를 위한 시스템 | |
JP5677559B2 (ja) | シート状細胞培養物の製造方法 | |
CN112771153A (zh) | 动物细胞培养用添加物、培养用培养基和培养方法 | |
CN112852715B (zh) | 将诱导多能干细胞定向分化为内耳毛细胞样细胞的方法 | |
JP5770921B2 (ja) | シート状細胞培養物の製造方法 | |
JP2014143971A (ja) | シート状細胞培養物の製造方法 | |
CN111662867A (zh) | 一种人牙髓细胞分离培养方法 | |
JP6546219B2 (ja) | シート状細胞培養物の製造方法 | |
CN116327889B (zh) | 一种调节剂在心脏病治疗中的应用 | |
RU2795065C1 (ru) | Состав бессывороточной питательной среды для культивирования мезенхимных стволовых клеток свиньи | |
US20220204909A1 (en) | Modular continuous flow bioreactor | |
JP7058314B2 (ja) | 医療用細胞シートの製造方法 | |
JP6801042B2 (ja) | 医療用細胞シートの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221011 |